Pfizer will acquire Arena Pharmaceuticals to enhance chronic disease management, including accelerating development of etrasimod for patients with immuno-inflammatory diseases.
Pfizer recently entered into a $6.7 billion proposed pharma acquisition deal with Arena Pharmaceuticals to develop therapies for chronic disease management.
Arena Pharmaceutical
